Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response

International Journal of Cancer

Volumn 119, Issue 2, 2006, Pages 406-413

  Matsuyama, Ryusei ^a,b   Togo, Shinji ^a,c   Shimizu, Daisuke ^a,b   Momiyama, Nobuyoshi ^a   Ishikawa, Takashi ^a   Ichikawa, Yasushi ^a   Endo, Itaru ^a   Kunisaki, Chikara ^a   Suzuki, Harukazu ^b   Hayasizaki, Yoshihide ^b   Shimada, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Chemosensitivity; Colorectal cancer; Liver metastasis; Prediction

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC SELECTION; HUMAN; LIVER METASTASIS; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; UNINDEXED SEQUENCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; CYTOKINES; DIHYDROURACIL DEHYDROGENASE (NADP); DISCRIMINANT ANALYSIS; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OROTATE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33745076752     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21843     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Kune GA, Kune S, Field B, White R, Brough W, Schellenberger R, Watson LF. Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 1990;33:938-46.
3. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
5. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
6. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
7. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, TsaoWei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
8. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayashizaki Y, Okazaki Y, Danenberg PV, Shimada H. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 2005;27:371-6.
9. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma, 1st English ed. Tokyo: Kanehara, 1997. 18p.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
11. Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, Vidaud M. Gene expression profiling in clinically localized prostate cancer, a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003;9:5477-85.
12. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
13. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
14. Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Nakamura Y, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 2002;1:1035-42.
15. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001;61:6474-9.
16. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001;37:1681-7.
17. Takechi T, Koizumi K, Tsujimoto H, Fukushima M. Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn J Cancer Res 2001;92:696-703.
18. Ota M, Shimada H, Masui H, Tanaka K, Yamaguchi S, Ichikawa Y, Togo S, Ike H, Oki S. Adjuvant hepatic arterial infusion chemotherapy after curative resection for Dukes C colorectal cancer: a pilot study. Hepatogastroenterology 2004;51:124-7.
19. Shimada H, Tanaka K, Masui H, Nagano Y, Matsuo K, Togo S. Results of surgical treatment for multiple (> or = 5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg 2004;389:114-21.
20. Tanaka K, Shimada H, Kubota K, Ueda M, Endo I, Sekido H, Togo S. Effectiveness of prehepatectomy intra-arterial chemotherapy for multiple bilobar colorectal cancer metastases to the liver: a clinicopathologic study of peritumoral vasculobiliary invasion. Surgery 2005;137:156-64.
21. Seitz C, Muller P, Krieg RC, Mannel DN, Hehlgans T. A novel p75TNF receptor isoform mediating NFκ B activation. J Biol Chem 2001;276:19390-5.
22. Chainy GB, Singh S, Raju U, Aggarwal BB. Differential activation of the nuclear factor-κ B by TNF muteins specific for the p60 and p80 TNF receptors. J Immunol 1996;157:2410-7.
23. McFarlane SM, Pashmi G, Connell MC, Littlejohn AF, Tucker SJ, Vandenabeele P, MacEwan DJ. Differential activation of nuclear factor-κB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. FEBS Lett 2002;515:119-26.
24. Hehlgans T, Mannel DN. The TNF-TNF receptor system. Biol Chem 2002;383:1581-5.
25. Ishida N, Kawakita M. Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflugers Arch 2004;447:768-75.
26. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-8.
27. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Klamut HJ. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000;275:20127-35.
28. Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003;105:747-53.
29. Tan M, Wang Y, Guan K, Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci USA 2000;97:109-14.
30. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003;8:72-8.
31. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Hirayama R, Nihei Z, Sugihara K, Sasaki Y. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92.
32. Kommann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U, Leder GH, Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
33. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3:75-82.
34. Aschele C, Debemardis D, Tunesi G, Maley F, Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000;6:4797-802.
35. Johnston PG, Benson AB, III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-9.
36. Shirota Y, Ichikawa W, Uetake H, Yamada H, Nihei Z, Sugihara K. Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. Ann Surg Oncol 2002;9:599-603.
37. Yamagishi S, Shimada H, Ishikawa T, Fujii S, Tanaka K, Masui H, Yamaguchi S, Ichikawa Y, Togo S, Ike H. Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy. Anti Can Res 2005;25:1237-42.